Natural innate cytokine response to immunomodulators and adjuvants in human precision-cut lung slices.

First published in Toxicology and Applied Pharmacology on 2010 Aug.
Toxicol Appl Pharmacol. 2010 Aug 1;246(3):107-15. doi: 10.1016/j.taap.2010.04.010.

Authors: S.Switalla, L.Lauenstein, F.Prenzler, S.Knothe, C.Förster, H.-G.Fieguth, O.Pfennig, F.Schaumann, C.Martin. C.A.Guzman, T.Ebensen, M.Müller, J.M.Hohlfeld, N.Krug, A.Braun, K.Sewald

Abstract

Prediction of lung innate immuno responses is critical for developing new drugs. Well-established immuno modulators like lipopolysaccharides (LPS) can elicit a wide range of immunological effects. They are involved in acute lung diseases such as infections or chronic airway diseases such as COpharmacodynamics. LPS has a strong adjuvant activity, but its pyrogenicity has precluded therapeutic use. The bacterial lipopeptide MALP-2 and its synthetic derivative BPPcysMPEG are better tolerated. We have compared the effects of LPS and BPPcysMPEG on the innate immuno response in human precision-cut lung slices. Cytokine responses were quantified by ELISA, Luminex, and Meso Scale Discovery technology. The initial response to LPS and BPPcysMPEG was marked by coordinated and significant release of the mediators IL-1β, MIP-1β, and IL-10 in viable PCLS. Stimulation of lung tissue with BPPcysMPEG, however, induced a differential response. While LPS upregulated IFN-γ, BPPcysMPEG did not. This traces back to their signaling pathways via TLR4 and TLR2/6. The calculated exposure doses selected for LPS covered ranges occurring in clinical studies with human beings. Correlation of obtained data with data from human BAL fluid after segmental provocation with endotoxin showed highly comparable effects, resulting in a coefficient of correlation >0.9. Furthermore, we were interested in modulating the response to LPS. Using dexamethasone as an immunosuppressive drug for anti-inflammatory therapy, we found a significant reduction of GM-CSF, IL-1β, and IFN-γ. The PCLS-model offers the unique opportunity to test the efficacy and toxicity of biological agents intended for use by inhalation in a complex setting in humans.

 
 

Read more

Download full article as Pdf file:

Pdf File

 

REACHING OUT IS EASY AND FAST – LET’S TALK

Martin Mulder

Senior Vice President Corporate & Business Development


LET’S TALK BUSINESS